February MIMS update

Guest Author 06/02/2025

Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products RelabotulinumtoxinA (Relfydess) is a Clostridium botulinum type A neurotoxin product that blocks the release of acetylcholine from the presynaptic cholinergic neuronal synapse to produce muscle relaxation. The heavy chain of botulinum toxin type A mediates attachment to the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

February MIMS update

Previous January MIMS Update

Next Co-payment cut restored ‘dignity’ at dispensaries

MENU

ajp.com.au

Previous January MIMS Update

Next Co-payment cut restored ‘dignity’ at dispensaries

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.